Wczytywanie spółki
Just reported
Q3 2026 results
From Regeneron Pharmaceuticals's results release of 30 października 2026; its quarterly report has since been filed.
Revenue
Actual
5,12B USD
+36% y/y
+19% q/qGuided
—
No guide given
EPS, GAAP
Actual
18,45 USD
+35% y/y
+51% q/qGuided
—
No guide given
Operating income, GAAP
Actual
2,05B USD
+99% y/y
+58% q/qGuided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Regeneron Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,5B USDA+
EXELExelixis, Inc.17B USDA+
JAZZJazz Pharmaceuticals plc15,4B USDA
HALOHalozyme Therapeutics, Inc.11,5B USDA+
TECHBIO-Techne Corp11,4B USDA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 paź 2026CBGraded C, now B
MCKMckesson Corporation4 lis 2026BAGraded B, now A
CVSCVS Health Corp4 lis 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 lis 2026BAGraded B, now A
BIIBBiogen Inc.28 paź 2026BAGraded B, now A
Jak zarabia
- Collaboration revenue47%
- Product revenue38%
- Libtayo net product sales11%
- Product and service other4%
- Lynozyfic0%
Udziały w przychodach to szacunki za quarter ended March 31, 2026, a nie dane z raportu złożonego do regulatora.
Konkuruje z
Co sprzedaje6
Dupixent
An injected medicine used for several allergic and inflammatory conditions, including eczema, asthma, and chronic obstructive pulmonary disease.
EYLEA HD
An injection into the eye for retinal diseases, including wet age-related macular degeneration and diabetic macular edema.
EYLEA
An injection into the eye for retinal diseases, including wet age-related macular degeneration and diabetic macular edema.
Pokaż 3 więcej
Libtayo
An immune-system cancer medicine used for several cancers, including certain skin cancers and lung cancer.
Praluent
An injected medicine that lowers cholesterol and reduces cardiovascular risk in some patients.
Otarmeni
A gene therapy for hearing loss caused by changes in the otoferlin gene.
Kto to kupuje2
- Drug wholesalers and specialty distributors buy medicines for supply to pharmacies, hospitals, and other healthcare providers.
- Pharmacies, hospitals, government agencies, physicians, and other healthcare providers buy or use Regeneron medicines for patients.
Na czym się opiera i co może to zburzyć
Od czego zależy ta działalność
- 1A small number of customers together accounted for 77% (year ended December 31, 2025, high) of gross product revenue.
- 2Sales depend substantially on Dupixent, EYLEA HD, and EYLEA, and on continued commercial work with Sanofi and Bayer.
- 3Some medicines rely on single-source suppliers and on collaborators or contractors for filling, packaging, testing, and distribution.
- 4Sales depend on health insurers and government programs deciding whether to cover medicines and how much to reimburse.
Co może pójść nie tak
- 1EYLEA faces competition from other retinal medicines and biosimilars; the company has reported lower EYLEA sales as patients switch to EYLEA HD and other treatments compete for use.
- 2A large share of revenue depends on a few medicines and on partner arrangements, so lower sales, reduced reimbursement, or a change to a collaboration could materially affect revenue.
- 3Clinical studies can fail and regulators can delay or reject applications; recent examples include a fianlimab cancer study that missed its main goal and discontinued development of itepekimab in several respiratory conditions.
Pełne sprawozdania finansowe →
O spółce Regeneron Pharmaceuticals, Inc.
Regeneron discovers, develops, makes, and sells medicines for conditions including eye diseases, allergic and inflammatory diseases, and cancer. Its medicines include Dupixent for inflammatory diseases, EYLEA for retinal conditions, and Libtayo for cancer. It sells some medicines itself and shares sales profits with partners such as Sanofi and Bayer, which also sell certain medicines.
- Siedziba
- Tarrytown, New York
- Rok założenia
- 1988
- Notowana na
- NASDAQ
- Koniec roku obrotowego
- December 31
Zbudowane z własnych raportów spółki Regeneron Pharmaceuticals, Inc. składanych do amerykańskiej Komisji Papierów Wartościowych i Giełd (SEC). Liczby są takie, jak zaraportowano, a historia na akcję przeliczona na dzisiejszą bazę akcji. To opisuje firmę — nie jest poradą inwestycyjną ani rekomendacją kupna lub sprzedaży.